Fig. 9: Targeting NAT10 combined with anti-PD-L1 therapy improves the immune microenvironment and inhibits pancreatic cancer progression. | Cell Death & Disease

Fig. 9: Targeting NAT10 combined with anti-PD-L1 therapy improves the immune microenvironment and inhibits pancreatic cancer progression.

From: Targeting the ac4C ‘Writer’ NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells

Fig. 9: Targeting NAT10 combined with anti-PD-L1 therapy improves the immune microenvironment and inhibits pancreatic cancer progression.

A Schematic diagram of the combination therapy mouse model using an anti-PD-L1 antibody and Remodelin. B, C Compared with single agent therapy, combination therapy significantly reduced tumor weight (P < 0.001). D–F Flow cytometry analysis demonstrated that, compared with monotherapy, combination therapy significantly increased CD8 + T-cell infiltration and granzyme B expression (P < 0.001). G Graphical abstract depicting how NAT10 promotes pancreatic cancer immunosuppression and malignant progression through ac4C acetylation-mediated regulation of ETS2 and KRT8, highlighting its therapeutic potential in combination with anti-PD-L1 therapy.

Back to article page